Since (i) ASPP2 binds p53 and stimulates p53-dependent apoptosis and (ii) attenuated ASPP2 expression correlates with poor clinical outcome in aggressive DLBC lymphomas[17], we hypothesized that attenuated ASPP2 expression is related to poor clinical outcomes in AML. This evidence concerns the gene TP53 and lymphoma.